Sarepta's stock price plummets after an 'erroneous' report - STAT - STAT

It was not an executive shakeup that pummeled shares of Sarepta Therapeutics (SRPT) on Thursday. It was not rumors of a takeover Wall Street didn’t like.
Instead, it was a mistake.





Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTED




What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?
Daily reporting and analysis
The most comprehensive industry coverage from a powerhouse team of reporters
Subscriber-only newsletters
Daily newsletters to brief you on the most important industry news of the day
Online intelligence briefings
Frequent opportunities to engage with veteran beat reporters and industry experts
Exclusive industry events
Premium access to subscriber-only networking events around the country
The best reporters in the industry
The most trusted and well-connected newsroom in the health care industry
And much more
Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.






Kate Sheridan


General Assignment Reporter
Kate is a general assignment reporter.





Read More